Sin spam. Cancela en cualquier momento.
Análisis de Pureza HPLC
Retatrutide 20mg + Tirzepatide 40mg
CAS: 2023788-19-2
Estudiado para máxima cobertura de receptores metabólicos
Retatrutide 20mg + Tirzepatide 40mg is a research peptide in the glp-1 / weight management category. Tirzepatide is a dual GIP and GLP-1 receptor agonist that activates both incretin pathways simultaneously. MiPeptidos offers Retatrutide 20mg + Tirzepatide 40mg in 1 sizes with 99.1% verified purity and full analytical documentation.
- All 3 metabolic pathways
- Enhanced calorie burning
- Powerful appetite suppression
- Stubborn fat targeting
This is an advanced combination pairing a triple-agonist (retatrutide) with a dual-agonist (tirzepatide) for maximum receptor coverage across GLP-1, GIP, and glucagon pathways. Research suggests appetite suppression and thermogenic effects begin within the first week. By weeks 8-16, studies report accelerated fat loss including in stubborn areas, driven by the glucagon receptor activation from retatrutide on top of tirzepatide's potent dual-pathway effects. This is an investigational combination — no human trials have studied these agents together.
$147.40/vial · Everything you need to start
Sin spam. Cancela en cualquier momento.
Análisis de Pureza HPLC
Maximum Receptor Coverage.
24-week ultra protocol combining two of the most potent incretin-class agents in development
This combination protocol pairs retatrutide (triple GIP/GLP-1/glucagon agonist) with tirzepatide (dual GIP/GLP-1 agonist) to achieve maximum incretin receptor coverage. The rationale: retatrutide contributes glucagon receptor agonism for energy expenditure and hepatic fat clearance, while the higher tirzepatide dose provides potent dual incretin satiety and insulin sensitization.
Resultados Publicados
Revisado por ParesResultados cuantificables de investigación clínica publicada.
Lo que Dicen los Expertos
4 MédicosProfesionales e investigadores líderes que han estudiado y prescrito este péptido.
Dr. Matthias Tschöp
CEO, Helmholtz Munich; Professor of Metabolic Diseases, Technical University of Munich
Pioneer of poly-agonist metabolic pharmacology. Conceptualized the multi-receptor approach that led to development of both tirzepatide and retatrutide.
The ultimate goal of unimolecular poly-agonism is to engage every relevant metabolic receptor simultaneously. Combining a triple agonist with a dual agonist pushes this concept to its limit.
Any combination of potent incretin agents must be approached with extreme caution regarding GI tolerability and metabolic monitoring. Start both at minimal doses and escalate independently.
Fuente: Nature Reviews Drug Discovery poly-agonist reviews; Helmholtz Munich research
Dr. Daniel Drucker
Professor of Medicine, University of Toronto; Lunenfeld-Tanenbaum Research Institute
Foremost expert on GLP-1 biology. Discovered GLP-1's insulinotropic properties. Canada Gairdner International Award recipient.
Combining incretin agents is a logical extension of the poly-agonist paradigm, but the safety implications of overlapping GLP-1 and GIP stimulation from two sources must be carefully evaluated.
The glucagon component of retatrutide is what makes this combination potentially unique — tirzepatide alone cannot increase energy expenditure through hepatic glucagon pathways. Monitor liver function and glucose closely.
Fuente: Cell Metabolism incretin biology reviews; University of Toronto research
Dr. Peter Attia
Physician, Founder of Attia Medical PC
MD from Stanford. Longevity medicine specialist. Extensively covers incretin-based therapies on The Drive podcast.
Stacking incretin agents is the frontier of metabolic pharmacology. The key question is whether the glucagon agonism from retatrutide provides meaningful additive benefit on top of maximum-dose tirzepatide.
This combination should only be considered after maximizing single-agent therapy. Monitor DEXA body composition, liver function, and metabolic panels every 4-6 weeks. Protein and resistance training are non-negotiable.
Fuente: The Peter Attia Drive Podcast: GLP-1 and poly-agonist discussions
Dr. Ania Jastreboff
Director, Yale Obesity Research Center
Lead investigator of both SURMOUNT-1 (tirzepatide) and the retatrutide Phase 2 obesity trial. MD, PhD.
Both tirzepatide and retatrutide individually produce remarkable weight loss. Whether combining them provides benefit beyond either agent at maximum dose is a critical unanswered question.
If pursuing combination protocols, start with sub-therapeutic doses of both agents and escalate slowly. The GI side effect burden of two potent incretin agents simultaneously requires careful titration.
Fuente: Yale obesity research; NEJM trial publications
Protocolo de Dosificación
3 FasesRégimen de dosificación paso a paso compilado de profesionales líderes e investigación clínica.
CRITICAL: Start both agents at their minimum effective doses. Combining two potent incretin agents dramatically increases GI risk. Assess tolerability before any escalation.
Escalate one agent at a time every 4 weeks — never increase both simultaneously. Monitor GI tolerability closely. If nausea is significant, hold doses for additional 4 weeks.
Intermediate combination dose. Many protocols will stabilize here. Escalation to maximum doses (12mg+15mg) should be approached with extreme caution and medical oversight.
Reconstitute the 60mg combo vial (20mg retatrutide + 40mg tirzepatide) with 2mL bacteriostatic water. This yields 10mg retatrutide/mL + 20mg tirzepatide/mL. Draw appropriate volumes for each weekly dose. Use separate syringes if splitting doses.
No cycling data exists for this combination. Both components are designed for continuous use. If discontinuing, taper both agents gradually over 4-8 weeks to minimize rebound. Monitor weight and metabolic parameters during taper.
Lyophilized: store at -20°C. Reconstituted: refrigerate at 2-8°C, use within 30 days. Protect from light. Both peptides are stable in co-formulated lyophilized powder.
Can be administered as a single injection from the combo vial or as two separate injections. If splitting, inject at different sites at least 5cm apart. Same day each week. Sequential escalation means adjusting only one component at a time.
Cronología de Recuperación
Basado en observaciones de investigación publicada. Los resultados individuales varían. Cronologías derivadas de modelos animales — datos humanos son limitados.
Dual-Agent Initiation & GI Assessment
- Four receptor pathways activating: GIP (both agents), GLP-1 (both), glucagon (retatrutide only)
- Appetite suppression from overlapping GLP-1 activation begins quickly
- GI side effects may be more intense than either agent alone — careful monitoring
- Glucose and insulin homeostasis improving from dual incretin engagement
- Typical weight loss: 3-5% of body weight
Base de investigación: Extrapolated from SURMOUNT-1 and retatrutide Phase 2 individual dose-response curves
Sequential Dose Escalation & Multi-Pathway Engagement
- One agent escalated at a time to isolate tolerability
- Retatrutide's glucagon component increasing resting energy expenditure
- Tirzepatide's GIP/GLP-1 providing potent appetite suppression and insulin sensitization
- Metabolic parameters (glucose, triglycerides, liver enzymes) require 4-week monitoring
- Typical weight loss: 10-16% of body weight
Base de investigación: Individual dose-response data from SURMOUNT-1 (PMID: 35658024) and retatrutide Phase 2 (PMID: 37351564)
Intermediate Combination & Maximum Effect Potential
- Retatrutide 8mg + tirzepatide 10mg provides substantial multi-pathway coverage
- Glucagon-mediated thermogenesis + maximal incretin appetite suppression
- Liver fat content expected to decrease substantially from glucagon + metabolic improvement
- Weight loss trajectory may exceed either agent alone at equivalent timepoints
- Typical weight loss: potentially 18-26% of body weight (theoretical extrapolation)
Base de investigación: Theoretical extrapolation from individual agent Phase 2-3 data; no combination trial data
Long-Term Monitoring & Protocol Assessment
- Ongoing monitoring of liver function, metabolic panels, and body composition is essential
- Assess whether combination provides meaningful benefit over single-agent maximum dose
- Consider stepping down to single agent if weight loss goals achieved
- No long-term safety data for the combination — vigilant monitoring required
- Cardiovascular, hepatic, and pancreatic outcomes monitoring recommended
Base de investigación: No published data — this is an investigational combination requiring physician oversight
Mecanismo de Acción
3 vías biológicas distintas a través de las cuales opera este péptido.
Maximum Incretin Receptor Saturation
Both agents activate GIP and GLP-1 receptors, providing maximum saturation of these pathways for appetite suppression, insulin sensitization, and glucose control.
- Overlapping GLP-1R activation from both agents ensures maximum hypothalamic appetite suppression
- Dual GIP activation provides robust insulin sensitivity enhancement in adipose tissue
- Higher combined incretin exposure may overcome receptor desensitization
- Risk: overlapping GI side effects from double gastric emptying delay
SURPASS-2 (PMID: 34170646); retatrutide Phase 2 (PMID: 37351564)
Glucagon-Mediated Energy Expenditure (Unique to Retatrutide)
Retatrutide's glucagon receptor component is the key differentiator — tirzepatide cannot activate this pathway. Glucagon drives hepatic lipid oxidation and thermogenesis.
- Glucagon activates hepatic CPT1a for fatty acid oxidation
- Increases resting metabolic rate through non-shivering thermogenesis
- Drives FGF21 release for white adipose tissue browning
- This pathway is absent in tirzepatide — only retatrutide provides it
Day et al. (2021) Nature Reviews Drug Discovery; retatrutide mechanism studies
Hepatic Fat Clearance (Synergistic)
Retatrutide's glucagon-driven hepatic oxidation combined with tirzepatide's metabolic improvement provides multi-mechanistic liver fat clearance.
- Glucagon directly oxidizes hepatic fat via mitochondrial fatty acid pathways
- GIP/GLP-1 improve systemic insulin resistance, reducing hepatic lipogenesis
- Combined effect may exceed either agent's liver fat reduction alone
- Particularly relevant for MASH/NASH-focused protocols
Retatrutide liver fat substudy data; tirzepatide MASH trials
Investigación Publicada
4 estudios revisados por pares de PubMed. Haz clic en cualquier PMID para ver el estudio completo.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff AM, Kaplan LM, Frías JP, et al. — New England Journal of Medicine (2023)
Hallazgo Clave: Retatrutide 12mg: 24.2% weight loss at 48 weeks. The triple-agonist component of this combination provides glucagon-mediated energy expenditure that tirzepatide alone cannot.
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
Jastreboff AM, Aronne LJ, Ahmad NN, et al. — New England Journal of Medicine (2022)
Hallazgo Clave: Tirzepatide 15mg: 22.5% weight loss at 72 weeks. The dual-agonist component provides the most potent GIP/GLP-1 engagement available for appetite suppression and insulin sensitization.
Tirzepatide versus Semaglutide in Type 2 Diabetes (SURPASS-2)
Frías JP, Davies MJ, Rosenstock J, et al. — New England Journal of Medicine (2021)
Hallazgo Clave: Tirzepatide nearly doubled semaglutide's weight loss. Establishes tirzepatide as the more potent dual agonist, justifying its selection as the GIP/GLP-1 component in this combination.
Glucagon receptor agonism in obesity treatment: unimolecular poly-agonist approach
Day JW, Ottaway N, Patterson JT, et al. — Nature Reviews Drug Discovery (2021)
Hallazgo Clave: Foundational review establishing the rationale for glucagon co-agonism: energy expenditure increase, hepatic fat clearance, and synergy with GLP-1 appetite suppression. Supports combining glucagon-active and incretin-active agents.
Potencia tu Protocolo de Investigación
3 SinergiasLa investigación sugiere combinar Retatrutide 20mg + Tirzepatide 40mg con estos péptidos para mecanismos complementarios.
With two potent incretin agents affecting gastric emptying simultaneously, GI protection is not optional — it is essential for tolerability.
May be the difference between tolerating the combination and having to discontinue. Critical during dose escalation phases.
Potentially the most aggressive pharmacological weight loss protocol available — lean mass preservation via GH support is non-negotiable.
Absolutely critical. Without GH support and resistance training, this level of weight loss would cause dangerous lean mass depletion.
Tesamorelin specifically targets visceral and hepatic fat, synergizing with retatrutide's glucagon-mediated liver fat clearance component.
Triple approach to visceral fat: glucagon oxidation + GH-mediated lipolysis + incretin-driven caloric deficit. Particularly relevant for metabolic syndrome and MASH.
Especificaciones
Cómo Funciona Retatrutide 20mg + Tirzepatide 40mg
Tirzepatide is a dual GIP and GLP-1 receptor agonist that activates both incretin pathways simultaneously. It stimulates insulin secretion, suppresses glucagon in a glucose-dependent manner, and reduces appetite via central and peripheral signaling. The dual receptor engagement provides synergistic metabolic effects beyond GLP-1 agonism alone, including enhanced lipid metabolism and improved insulin sensitivity.
Aplicaciones de Investigación
Precios
| Tamaño | Por Vial | Paquete de 10 |
|---|---|---|
60mg (20mg+40mg) | $240.00 | $2040.00 |
Precios de paquete de 10 mostrados. Descuentos por volumen para 50+ viales — contáctenos.
Certificado de Análisis
Este COA es una muestra representativa. Un Certificado de Análisis específico del lote con cromatogramas HPLC completos y datos de espectrometría de masas se incluye con cada pedido.
Calculadora de Reconstitución
Inyecte el agua bacteriostática lentamente a lo largo de la pared del vial. Agite suavemente hasta disolver — nunca sacuda. Almacene la solución reconstituida a 2-8°C y use dentro de 30 días.
Reseñas de Clientes
Preguntas Frecuentes
Seguridad y Advertencias
No clinical data exists for this combination
This combination has NEVER been studied in humans. Both agents are individually investigational (retatrutide) or recently approved (tirzepatide). The safety profile of co-administration is completely unknown. Physician oversight is absolutely required.
Overlapping GLP-1 and GIP receptor activation risks
Both agents activate GLP-1 and GIP receptors. Overlapping stimulation may amplify pancreatitis risk, thyroid C-cell tumor risk, and severe GI events beyond what either agent produces alone.
Severe GI event risk from dual gastric emptying delay
Two agents slowing gastric emptying simultaneously creates high risk for severe nausea, vomiting, and potentially gastroparesis. Start at minimal doses and escalate only one agent at a time.
Hypoglycemia risk from combined insulin potentiation
Both agents enhance insulin secretion. While individually glucose-dependent, combined exposure may lower the glucose threshold for hypoglycemia. Monitor blood glucose frequently.
Solo para Fines de Investigación y Educación. No es consejo médico. No para consumo humano. Consulte a un médico autorizado antes de tomar cualquier decisión relacionada con la salud.
Péptidos Relacionados
Up to 50% OffSemaglutide
Estudiado clínicamente para una reducción de peso constante — una vez por semana
Up to 60% OffTirzepatide
El agonista dual más estudiado para la reducción de peso
Up to 42% OffRetatrutide
Agonista de triple receptor estudiado para una actividad metabólica mejorada
Up to 38% OffLiraglutide
GLP-1 diario estudiado para la regulación constante del apetito